^
    Back
    Association details:
    Biomarker:CD276 expression
    Cancer:Neuroblastoma
    Drug:vobramitamab duocarmazine (MGC018) (DNA replication inhibitor, B7-H3-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Immunother Cancer
    Title:

    Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

    Published date:
    09/30/2023
    Excerpt:
    Vobra duo treatment for 4 weeks further increased survival in both orthotopic and resected NB models….Vobra duo exerts relevant antitumor activity in preclinical B7-H3-expressing NB models…
    DOI:
    10.1136/jitc-2023-007174